A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment
Latest Information Update: 20 Aug 2026
At a glance
- Drugs Imlifidase (Primary) ; Immune globulin; Methylprednisolone; Rituximab
- Indications Kidney-pancreas transplant rejection
- Focus Pharmacodynamics
- Acronyms DINKY
- Sponsors Hansa Biopharma AB
Most Recent Events
- 22 Jun 2026 Planned number of patients changed from 10 to 12.
- 04 Feb 2025 Planned End Date changed from 30 Sep 2029 to 31 Aug 2031.
- 04 Feb 2025 Planned primary completion date changed from 30 Sep 2024 to 28 Feb 2027.